On January 3, 2017, Peter R. Culpepper sent the Board a letter in which he stated that by abruptly terminating his involvement with the Provectus Biopharmaceuticals, Inc., while the Company was in the process of seeking financing it needs its 2 prescription drug candidates, the Board is putting the business of the Company in severe jeopardy. Peter R. Culpepper viewed that at least the current non-officer members of the Board should be replaced with people who have the background to be able to understand what the Company is required to do in order to get its prescription drug candidates approved and brought to market, and who will be willing to devote time and effort to overseeing the business endeavors of the Company. Peter R. Culpepper added that he may seek to cause the current directors of the Company to be replaced, may seek to cause the Company’s capital to be restructured in order to enhance the ability of the Company to obtain the financing it requires, may seek to identify purchasers for the Company or substantial interests in the Company, and may take other steps intended to maximize the likelihood that the Company’s prescription drug candidates will be approved and brought to market and otherwise maximize the Company’s value. Peter R. Culpepper added that he himself may participate in providing financing to the Company or in efforts to acquire the Company or substantial interests in it, and Culpepper may seek to be reinstated as a senior officer of the Company.